DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
Defense Health Agency Contracting Activity - DHACA
Free. Verify your email, then we send one reminder only.
- Posted
- May 4, 2026
- Amount
- Program total $7M
- Closes
- Sep 30, 2026 (in 15 days)
Similar opportunities open now
- DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 15 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 15 days
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 15 days
- DoW Autism Clinical Trial AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 37 days
- DoW Arthritis Clinical Research AwardSame funderOpenDefense Health Agency Contracting Activity - DHACACloses in 37 days
Classification and identifiers
- Solicitation number
- HT942526ALSRPCOBA
- Assistance listing (CFDA)
- 12.420
Amount
Program total $7M
Who can apply
About this opportunity
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Clinical Outcomes and Biomarkers Award (COBA) supports the development and/or validation of clinical outcomes and biomarkers to enrich clinical trials in amyotrophic lateral sclerosis (ALS). Projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. Distinctive Features: To meet the intent of the funding opportunity, applications may address clinical biomarkers and/or clinical outcomes . This may include the identification, development, and/or validation of promising biomarkers for ALS, which may include, but are not limited to susceptibility/risk, diagnostic, monitori...